Evidence map›Paper›PMID 28595285›Full record

Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2017

Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy.

F T Roncolato, E Gibbs, C K Lee, R Asher, L C Davies, V J Gebski, M Friedlander, F Hilpert, L Wenzel, M R Stockler and 2 more

Registry-linked trialAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00976911 (AURELIA), which is not on this map. Cited by 15 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00976911 phase3completednot on this map

AURELIA: A Multi-center, Open-label, Randomised, Two-arm Phase III Trial of the Effect on Progression Free Survival of Bevacizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

TypeinterventionalSponsorHoffmann-La RocheRan2009 to 2014Enrolled361ConditionsOvarian CancerArmsBevacizumab, liposomal doxorubicin, paclitaxel, topotecan
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Exploring the role of health-related quality of life measures in predictive modelling for oncology: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Pooled it
  3. Patient-Reported Quality-of-Life Outcome Measures in the Thyroid Cancer Population.Thyroid : official journal of the American Thyroid Association · 2020
    Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Physical and functional well-being and symptoms of ovarian cancer in women undergoing first-line of chemotherapy: a one-year follow-up.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

F T RoncolatoNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney.
E GibbsNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney.
C K LeeNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney.
R AsherNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney.
L C DaviesNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney.
V J GebskiNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney.
M FriedlanderMedical Oncology, Prince of Wales Hospital, Sydney, Australia.
F HilpertGynecology & Obstetrics, University of Schleswig-Holstein, Kiel, Germany.
L WenzelPublic Health, University of California, Irvine, USA.
M R StocklerNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney.
M KingPsycho-oncology Co-operative Research Group (PoCoG), University of Sydney, Sydney, Australia.
E Pujade-LauraineHematology & Medical Oncology, Hopital Hôtel-Dieu de Paris, Paris, France.

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Christine Hui · 1994 to 2026
$57.9M
NCI NIH HHS P30 CA062203
6 · The paper itself

Abstract

backgroundWomen with platinum-resistant ovarian cancer are a heterogeneous group whose median overall survival is 12 months. We hypothesized that their quality of life (QoL) scores would be prognostic. PATIENTS AND

methodsData from AURELIA (n = 326), a randomized trial of chemotherapy with or without bevacizumab, were used to identify baseline QoL domains [EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30 and OV28] that were significantly associated with overall survival in multivariable Cox regression analyses. Patients were classified as having good, medium, or poor risk. Cutpoints were validated in an independent dataset, CARTAXHY (n = 136). Multivariable analyses of significant QoL domains on survival were adjusted for clinicopathological prognostic factors. The additional QoL information was assessed using C statistic.

resultsIn AURELIA, all domains, except cognitive function, predicted overall survival in univariable analyses. Physical function (P < 0.001) and abdominal/gastrointestinal symptom (P < 0.001) scores remained significant in multivariable models. In high (score <67), medium (67-93), and low (>93) risk categories for physical function, median overall survival was 11.0, 14.7, and 19.3 months, respectively (P < 0.001). In CARTAXHY, median overall survival was 7.9, 16.2, and 23.9 months (P < 0.001), respectively. For high- (>44), medium- (13-44), and low- (<13) risk categories for abdominal/gastrointestinal symptoms, median overall survival was 11.9, 14.3, and 19.7 months in AURELIA (P < 0.001) and 10.5, 19.6, and 24.1 months in CARTAXHY (P = 0.02). Physical function (P = 0.02) and abdominal/gastrointestinal symptoms (P = 0.03) remained independent prognostic factors after adjustment for clinicopathological factors. The C statistic of the full model was 0.71. For QoL factors alone, patient factors alone and disease factors alone, the C statistics were 0.61, 0.61, and 0.67 respectively.

conclusionsPhysical function and abdominal/gastrointestinal symptom scores improved predictions of overall survival over clinicopathological factors alone in platinum-resistant ovarian cancer. This additional prognostic information could improve trial stratification, patient-doctor communication about prognosis, and clinical decision-making. CLINICAL

trial registrationNCT00976911.

Indexed as

Quality of LifeAntineoplastic Combined Chemotherapy ProtocolsBevacizumabDrug Resistance, NeoplasmFemaleHumansOrganoplatinum CompoundsOvarian NeoplasmsSurvival AnalysisBevacizumabOrganoplatinum Compoundspatient-reported outcomesplatinum-resistant ovarian cancerprognosisquality of life

Identifiers

PMID28595285
PMCPMC6410892

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.